Astrana Health SEC Filings

The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 4,238,192 shares of Astrana Health Inc common stock, representing 8.45% of the class as of the event date. Vanguard reports no sole voting or dispositive power, with 341,999 shares subject to shared voting power and all reported shares subject to shared dispositive power.

Vanguard states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Astrana Health. It also notes an internal realignment effective January 12, 2026, after which certain subsidiaries or business divisions are expected to report beneficial ownership separately while pursuing the same investment strategies.

Astrana Health, Inc.’s Chief Medical Officer, Dr. Dinesh M. Kumar, reported a tax-related share surrender. On January 23, 2026, he surrendered 10,759 shares of Astrana Health common stock at $27.16 per share to cover withholding taxes on vested restricted stock.

After this transaction, Dr. Kumar beneficially owned 202,032 shares of common stock. This amount includes time-based and performance-based restricted stock and restricted stock units, as well as shares previously acquired under the company’s employee stock purchase plan, all of which vest over future dates subject to continued employment and performance conditions.

Astrana Health director David Schmidt reported exercising stock options and related share withholding. On January 13, 2026, he exercised 20,000 stock options with an exercise price of $5.79 per share, receiving the same number of Astrana Health common shares.

On the same date, 4,269 common shares were withheld at a price of $27.12 in a transaction coded "F," typically reflecting shares withheld to cover taxes. After these transactions, Schmidt directly owned 31,494 common shares, which include 6,449 shares of restricted stock scheduled to vest on the earlier of June 11, 2026 or the issuer's 2026 annual stockholder meeting. The exercised option position was reduced to 0 derivative securities.

Astrana Health, Inc. furnished an updated corporate investor presentation that it plans to use at conferences and meetings. The slide deck, dated January 2026, is attached as Exhibit 99.1 and is provided for informational purposes only.

The company states that this material is being furnished rather than filed, which means it is not subject to certain liability provisions under securities laws and will not automatically be incorporated into other regulatory filings. The presentation contains forward-looking statements, and Astrana Health refers readers to its most recent annual and quarterly reports for a discussion of risks that could cause actual results to differ.

Astrana Health (ASTH) Executive Chairman and Director Kenneth T. Sim reported an insider transaction. On 11/10/2025, he exercised stock options at $17.78 to acquire 29,502 shares of common stock (transaction code M), bringing his direct holdings to 639,407 shares. He also reports indirect holdings, including 6,132,802 shares by Allied Physicians of California, 546,349 by the Kenneth T & Simone S Sim Family Trust, 42,996 by the Kenneth T. Sim Pension Plan Trust, and 230,688 by a grantor retained annuity trust. Unvested restricted stock included in his holdings comprises 117,501 shares vesting in three equal annual installments beginning on March 5, 2026, and 133,333 shares vesting upon achievement of pre-established performance goals.

Astrana Health (ASTH): A company director exercised stock options and acquired 20,000 shares of common stock at $18.20 on 11/10/2025. Following the transaction, the director directly owns 34,763 shares. This total includes 6,449 restricted shares that will vest on the earlier of June 11, 2026 or the company’s 2026 annual meeting of stockholders. The exercised option covered 20,000 underlying shares and now shows a remaining balance of 0.

Astrana Health (ASTH) reported Q3 2025 results and closed a large acquisition. Revenue for the quarter was $956.0 million, up from $478.7 million a year ago, driven by higher capitation revenue. Income from operations was $19.2 million versus $28.4 million last year. Net income attributable to Astrana was $0.4 million with diluted EPS of $0.01, compared to $16.1 million and $0.33 a year earlier.

For the nine months, revenue was $2.23 billion versus $1.37 billion, while net income attributable to Astrana was $16.5 million (diluted EPS $0.33) versus $50.1 million (diluted EPS $1.04) last year.

On July 1, 2025, Astrana acquired Prospect for $674.9 million, financed by a $707.3 million five‑year delayed draw term loan, significantly expanding its provider network. Goodwill rose to $863.3 million and intangible assets to $285.1 million at quarter‑end. Cash and cash equivalents increased to $462.2 million, and total debt (current and long‑term) was $1.05 billion. Operating cash flow for the nine months was $117.5 million. As of November 7, 2025, there were 56,288,415 common shares outstanding, including 6,132,802 treasury shares held by APC.

Astrana Health, Inc. furnished an update on its financial results for the three and nine months ended September 30, 2025. The company issued a press release and made an earnings presentation available, each furnished as exhibits.

A conference call and webcast are scheduled for 2:30 p.m. Pacific Time / 5:30 p.m. Eastern Time on November 6, 2025 to discuss the results. The materials are furnished, not filed, and are available on the investor relations site and as Exhibit 99.1 (press release) and Exhibit 99.2 (supplemental data).

Astrana Health (ASTH) director reported insider transactions on 11/03/2025. The filing shows an option exercise for 20,000 shares at $18.20 per share (Code M), followed by share withholding for taxes of 11,033 shares at $32.99 (Code F).

Following these transactions, the director beneficially owns 92,608 shares directly, which includes 6,449 restricted shares that vest on the earlier of June 11, 2026 or the 2026 annual meeting. The exercised options were fully vested and exercisable.